期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 30, 期 7, 页码 681-694出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2021.1893305
关键词
Fezolinetant; hot flashes; KNDy neuron; menopause; NK3 receptor antagonist; vasomotor symptoms
资金
- Ministry of Sustainable Development and Public Works, Walloon Region, Belgium
- Astellas Pharma Inc.
- OGEDA SA
Although international clinical practice guidelines recognize the continued role of menopausal hormone therapy (HT), concerns over safety and tolerability have led to the search for non-hormonal alternatives such as fezolinetant, a neurokinin-3 receptor (NK3R) antagonist. Fezolinetant has shown promising results in reducing VMS frequency and severity, presenting a potential non-hormonal option for menopausal symptom relief.
Introduction: Although international clinical practice guidelines recognize a continued role for menopausal hormone therapy (HT), particularly for symptomatic women <60 years of age or within 10 years of menopause, safety and tolerability concerns have discouraged HT use due to potential links with a perceived increased risk of hormone-dependent cancers, and an established risk of stroke and venous thromboembolism. There is therefore a need for safe, effective non-hormonal therapy for relief of menopausal vasomotor symptoms (VMS). Areas covered: This narrative review summarizes the dataset accrued for fezolinetant, a neurokinin-3 receptor (NK3R) antagonist in clinical development for menopause-associated VMS. Expert opinion: Altered signaling in neuroendocrine circuits at menopause leads to VMS wherein NK3R activity plays a key role to modulate the thermoregulatory center in a manner conducive to triggering the 'hot flash' response. Thus, a new generation of NK3R antagonists has entered clinical development to specifically target the mechanistic basis of VMS. Fezolinetant is the most advanced NK3R antagonist in terms of stage of clinical development. Results to date have demonstrated rapid and substantial reduction in VMS frequency and severity and associated improvements in health-related quality of life. NK3R antagonists offer a non-hormonal alternative to HT for the treatment of menopause-related VMS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据